



Current Agreements

Dealdoc

Co-development agreement for sustained release formulation of interferon 2a for chronic hepatitis B and C

Q Chip
Artes Biotechnology

Apr 30 2010

Co-development agreement for sustained release formulation of interferon 2a for chronic hepatitis B and C

Companies: [Q Chip](#)
[Artes Biotechnology](#)
Announcement date: Apr 30 2010

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Apr 30 2010
Industry sectors:	Biotech Drug delivery Pharmaceutical
Therapy areas:	Infectives » Viral » Hepatitis Infectives » Viral » Hepatitis » B Drug delivery Enabling technology
Technology types:	Oligonucleotide Peptides Processes Proteomics Screening
Deal components:	Co-development
Stages of development:	Formulation

Financials

Termsheet

Q Chip Ltd and ARTES Biotechnology have signed a Collaborative Agreement to explore the co-development of a new sustained release formulation of interferon alpha 2a for the treatment of chronic hepatitis B and C.

The study is designed to evaluate Q Chip's Q-Sphera™ peptide and protein delivery platform to develop a new sustained release microsphere formulation composed of biocompatible polymers loaded with interferon alpha 2a manufactured from ARTES' proprietary yeast *Hansenula polymorpha* expression system.

This first phase of the collaboration is expected to be completed by the end of 2010.

Press Release

Q Chip Ltd And ARTES Biotechnology Announce Collaboration to Develop New Injectable Sustained Release Formulations of Therapeutic Proteins 4/30/2010

Cardiff and Langenfeld, April 29th 2010 — Q Chip Ltd and ARTES Biotechnology GmbH announce that they have signed a Collaborative Agreement to explore the co-development of a new sustained release formulation of interferon alpha 2a for the treatment of chronic hepatitis B and C.

The study is designed to evaluate Q Chip's Q-Sphera™ peptide and protein delivery platform to develop a new sustained release microsphere formulation composed of biocompatible polymers loaded with interferon alpha 2a manufactured from ARTES' proprietary yeast *Hansenula polymorpha* expression system.

Q-Sphera™ is a highly enabling bio-encapsulation technology for the development of polymer based sustained release systems. No harsh solvents or manufacturing conditions are used in the production of drug (including peptides and proteins) loaded microspheres facilitating benign processing of labile molecules.

Hansenula based products, which are already marketed worldwide, are characterized by safety and cost efficiency superior to other microbial technologies. Interferon alpha 2a manufactured from *Hansenula* has proven to be better tolerated than the *E. coli* reference.

The collaboration aims to improve patient compliance and provide a more convenient dosing schedule compared with current marketed pegylated therapies through the development of a one month sustained release microsphere formulation. This first phase of the collaboration is expected to be completed by the end of 2010.

Q Chip Ltd – www.q-chip.com

Q Chip is a UK based biopharmaceutical company specialising in the development of sustained release peptide and protein therapeutics using its proprietary Q-Sphera™ bioencapsulation platform. In 2004 Q Chip developed the world's first fully-functioning MicroPlant™ platform for the production of commercial volumes of uniform, precisely-loaded microcapsules using a wide range of biocompatible polymers. Q Chip encapsulates pharmaceutical drugs into injectable microspheres for treatment of chronic diseases and cancers. Q Chip is developing two generic drugs, Q-Leuprolide and Q-Octreotide, for cancer treatment.

ARTES Biotechnology GmbH – www.artes-biotechnology.com

ARTES is a Germany-based biotechnology company specialized in recombinant protein production from yeast expression systems. ARTES offers generation of optimized production cell lines and processes from the proprietary yeast expression systems *Hansenula polymorpha* and *Arxula adeninivorans*. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld near Duesseldorf. The company focuses on contract R&D for white and red biotechnology products.

Filing Data

Not available.

Contract

Not available.